v3.26.1
Note 8 - Commitments and Contingencies (Details Textual)
12 Months Ended
Apr. 30, 2026
USD ($)
Sep. 27, 2022
USD ($)
Apr. 30, 2026
USD ($)
Apr. 30, 2025
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Jan. 31, 2026
Sep. 20, 2023
Dec. 31, 2013
USD ($)
Lessee, Operating Lease, Extension Term (Month)   64 months            
Lessee, Operating Lease, Monthly Payments   $ 13,129            
Lessee, Operating Lease, Annual Rent Increase   3.00%            
Operating Lease, Expense     $ 200,000 $ 200,000        
Lessee, Operating Lease, Discount Rate           12.00%    
Loss Contingency, Damages Sought, Value $ 180,000              
Technology Agreement [Member]                
Aggregate Payment of Royalties         $ 3,000,000      
Closing Quoted Share Price (in dollars per share) | $ / shares         $ 6,875      
Accrued Royalty Payment Benchmark         $ 3,500,000      
License Agreements [Member]                
Number of License Agreements             11  
Number of AI Cardiovascular Algorithms             13  
Number of Data Science Methods             2  
Number of Filed Patents             3  
First 2400 MyoVista Devices [Member] | Technology Agreement [Member]                
Royalty Payment Upon Sale of Devices               $ 500
Royalty Payment, Number of Devices to Sell               2,400
Devices After 2400 Until 3500000 is Paid [Member] | Technology Agreement [Member]                
Royalty Payment Upon Sale of Devices         200      
Royalty Expense         $ 3,500,000